Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between.
Share this article
Share this article
NEW YORK, June 1, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ( Kadmon or the Company ) (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-01797, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA).
Published: Jun 01, 2021
CAMBRIDGE, Mass. and TOKYO, June 1, 2021 /PRNewswire/
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator,
U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.
The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. The FDA also indicated that they are not currently planning to hold an Advisory Committee meeting to discuss the application.